Gentium S.p.a.

Crinos Industria Farmacobiologica S.p.a.

Gentium S.r.l.

Gentum S.p.a.

Laura Ferro

Roberto Porta

Massimo Iacobelli

Ennio Lanzarotti

Fabio Trento

Franco Cattaneo

Carmelo Carlo Stella

Paul Richardson

Benito Casu

Giuseppe Prino

Armando Cedro

Alessandro Massimo Gianni

Giancarlo Farolfi

Rodolfo Pescador

Manlio Palumbo

Barbara Gatto

Franco Lattuada

Elisabetta Esposito

Claudio Nastruzzi

Massimo Alessandro Gianni

Enea Menegatti

The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.

Formulation having mobilizing activity

Formulation having mobilising activity

The use of defibrotide as an anti-tumor agent, alone or in combination with other active ingredients with anti-tumor action, is described.

Formulations with anti-tumour action

The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.

DNA-based aptamers for human cathepsin G

A method for the treatment and/or prevention of mucositis due to an antitumour treatment which comprises the administration of a composition containing suiglicotide to a patient in needs of said antitumour treatment.

Use of sulglicotide for the treatment of mucositis

Method for determining the biological activity of defibrotide by a) bringing into contact defibrotide, plasmin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide.

Method for determining the biological activity of defibrotide

The invention relates to the use as medicaments, specifically as antiinflammatories, of complexes formed by cationic liposomes and polydeoxyribonucleotides having a molecular weight in the range 7,000-60,000 Da obtainable by depolymerization of nucleic acids, wherein in said complexes the polydeoxyribonucletoides are located on the outer surface of the liposome.

Use of complexes among cationic liposomes and polydeoxyribonucleotides and medicaments

Fucans with low molecular weight having anticoagulant, antithrombinic and antithrombotic activity. Fucan sulfates having molecular weight between 14000 and 29000 Dalton show a remarkable anticoagulant activity both in the global coagulation mechanism (APTT) and in the last phase of coagulation (antithrombinic activity). These compounds are useful also as antithrombotic drugs.

Fucans with low molecular weight having anticoagulant, antithrombinic

The invention discloses new compositions of mesalazine in the form of aqueous suspensions, characterized in that they are more stable than those of the prior art. The compositions contain colloidal cellulose and one or more hydrophilic thickening agents.

Stable aqueous suspensions of mesalazine

A pharmaceutical composition comprising a polydeoxyribonucleotide of random sequence formula is disclosed, and

Use of polydeoxyribonucleotides in diabetic neuropathies

Polysaccharides and more in particular glycosaminoglycans, their mixtures, fractions and derivatives thereof are effective agents in the therapy of acute peripheral neuropathies of traumatic and ischemic origin and in the therapy of acute peripheral neuropathies of toxic origin.

Growing community of inventors

Milan, Italy

Laura Ferro